Kilitch Drugs Divests Ethiopian Subsidiary For USD 12.86M Following Debt-To-Equity Conversion
Kilitch Drugs India Ltd 路 Others (Uncategorized) 路 23 Oct 2026, 1:48 am
Kilitch Drugs Divests Ethiopian Subsidiary For USD 12.86M Following Debt-To-Equity Conversion Kilitch Drugs' board approved divesting its entire stake in Ethiopian subsidiary Kilitch Estro Biotech PLC (KEB) to state-owned HarmeeCare Pharmaceuticals for USD 14.0M total consideration, with USD 12.86M due to the company. Target completion is 31st Jan'27. Prior to divestment, Kilitch will convert up to INR 57.00 Cr outstanding debt into 1,66,472 KEB equity shares at Rs. 3,414 each by 30th Dec'26. In FY26, KEB contributed INR 47.57 Cr revenue (20.20% of consolidated) and negative INR 8.43 Cr net worth.
Original exchange filing (PDF)
More announcements from Kilitch Drugs India Ltd
- We are submitting Scrutinizer''s Report for evoting of EGM 路 16 Nov 2026
- Proceeding of EGM held today i.e. 16th November, 2026 路 16 Nov 2026
- Intimation under regulation 30 of the SEBI LODR regulations 2015, corrigendum to the Notice of Extra Ordinary General Meeting 路 13 Nov 2026
- We are submitting herewith the rectification of typo error in the outcome of Board meeting dated 22nd October, 2026 路 13 Nov 2026
- We are submitting herewith the outcome of the Board meeting 路 07 Nov 2026
- Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 07 Nov 2026
- Submitting unaudited financials results for quarter ended 30.09.2026 路 07 Nov 2026
- KILITCH DRUGS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 06 Nov 2026
